Daré Bioscience (NASDAQ:DARE) Stock Price Passes Below Two Hundred Day Moving Average of $4.59

Daré Bioscience, Inc. (NASDAQ:DARE)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.59 and traded as low as $3.43. Daré Bioscience shares last traded at $3.45, with a volume of 18,136 shares changing hands.

Analysts Set New Price Targets

Several research firms have recently issued reports on DARE. Brookline Capital Management upgraded shares of Daré Bioscience from a “hold” rating to a “buy” rating and set a $36.00 price objective on the stock in a report on Wednesday, May 15th. HC Wainwright reaffirmed a “buy” rating and issued a $72.00 price target on shares of Daré Bioscience in a report on Wednesday, May 15th. Finally, Maxim Group reissued a “hold” rating on shares of Daré Bioscience in a report on Wednesday, August 14th.

Daré Bioscience Price Performance

The firm has a market cap of $29.05 million, a P/E ratio of -0.90 and a beta of 1.37. The stock’s 50 day moving average is $3.49 and its two-hundred day moving average is $4.59.

Daré Bioscience (NASDAQ:DARE) last released its quarterly earnings data on Monday, August 12th. The biotechnology company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $2.09. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.60 million. As a group, research analysts forecast that Daré Bioscience, Inc. will post -0.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC boosted its position in shares of Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 778,700 shares of the biotechnology company’s stock after purchasing an additional 15,800 shares during the period. Renaissance Technologies LLC owned about 9.25% of Daré Bioscience worth $262,000 at the end of the most recent quarter. Institutional investors own 6.70% of the company’s stock.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.